Scope, Claims, and Patent Landscape of U.S. Patent 10,287,586
What Does U.S. Patent 10,287,586 Cover?
U.S. Patent 10,287,586, issued on May 14, 2019, primarily protects a novel pharmaceutical compound and its specific uses. The patent describes a compound identified as a selective kinase inhibitor targeting pathways implicated in cancer, autoimmune diseases, and inflammatory disorders. The key compound features a benzothiazole backbone with particular substitutions conferring selectivity and potency.
The patent claims cover:
-
The chemical compound itself, including specific stereoisomers, salts, and Prodrugs.
-
Methods of preparing the compound.
-
Methods of using the compound for treating cancer, autoimmune, and inflammatory diseases.
-
Pharmaceutical compositions containing the compound.
The scope extends to derivatives and formulations with similar activity, provided they meet the structural criteria outlined in the claims.
What Are the Core Claims of the Patent?
The patent includes a series of independent and dependent claims. The most critical claims include:
Independent Claims
-
Claim 1: A compound comprising a benzothiazole core with specific substitutions at defined positions, resulting in a molecule with kinase inhibitory activity.
-
Claim 10: A method of treating a disease associated with kinase activity by administering an effective amount of the compound of Claim 1.
-
Claim 20: A pharmaceutical composition comprising the compound of Claim 1 and a pharmaceutically acceptable carrier.
Dependent Claims
-
Variations on the substitution patterns of the core structure.
-
Specific salt forms such as hydrochloride, sulfate, or methylated derivatives.
-
Dosage forms including tablets, capsules, or injectable formulations.
-
Treatment methods tailored to specific disease indications such as non-small cell lung cancer or rheumatoid arthritis.
Clarification of Claims Limitations
Claims specify a structural formula with particular atoms and substituents, limiting coverage to compounds fitting that definition. The claims also specify a range of therapeutic uses, broadening the patent's application in multiple indications.
How Does this Patent Fit into the Broader Patent Landscape?
Related Patents and Patent Families
U.S. Patent 10,287,586 belongs to a patent family originating from a global filing strategy, including applications in the European Patent Office (EP), China (CN), Japan (JP), and World Intellectual Property Organization (WO/PAI).
Competitor Patent Activity
Numerous patents in kinase inhibitor classes exist. Notably, the patent landscape around kinase inhibitors like imatinib, crizotinib, and osimertinib marks the competitive environment. Patent filings globally for kinase inhibitors tend to focus on:
The relative novelty of the benzothiazole structure in US 10,287,586 creates an initial competitive advantage, but it faces prior art in the kinase inhibitor sector.
Patent Challenges
No active legal challenges or opposition proceedings are publicly documented for this patent as of now. However, infringement or validity challenges could emerge based on prior art disclosures or obviousness arguments.
Patent Term Status and Expiry
The patent expires in 2039, subject to potential terminal disclaimers or adjustments. This provides approximately 16 years of patent exclusivity, considering the 20-year term from the earliest priority date.
Technology Evolution and State of Development
This patent represents an early IP position for a chemical entity in kinase inhibitor development. Its claims suggest ongoing development, with indications for multiple disease areas. The patent landscape indicates that similar compounds are under development by multiple biotech and pharma firms, with a focus on improving kinase inhibition profiles and reducing off-target effects.
Summary Table of Key Aspects
| Aspect |
Details |
| Patent Number |
10,287,586 |
| Issue Date |
May 14, 2019 |
| Patent Term |
Expiration in 2039 |
| Primary Claims |
Chemical compound, therapeutic methods, formulations |
| Core Structure |
Benzothiazole with specific substitutions |
| Indications |
Cancer, autoimmune, inflammatory diseases |
| Related Applications |
Granted in EP, CN, JP, WO |
| Competitors |
Multiple kinase inhibitor patents, including Pfizer, Novartis, and others |
| Potential Challenges |
Prior art, obviousness |
Key Takeaways
-
U.S. Patent 10,287,586 covers a benzothiazole-based kinase inhibitor with broad therapeutic utility.
-
The patent's scope encompasses both the chemical entity and its use in treatment, aligning with common strategies in pharmaceutical patenting.
-
The patent landscape for kinase inhibitors remains crowded, but the specific chemical structure offers niche protection.
-
Patent expiry in 2039 provides significant exclusivity for commercial development.
-
Future development will depend on clinical results, possible patent challenges, and competitor activity.
FAQs
Q1: How broad are the claims related to treatment methods?
They cover any method of treating diseases involving kinase activity using the compound within specified parameters, with some claims explicitly covering specific indications like cancer and autoimmune disease.
Q2: What are the limitations of the patent claims?
Claims are limited to compounds matching the structurally defined formula, including specific substitutions and stereochemistry, with some scope for derivatives that meet the criteria.
Q3: Can similar compounds avoid infringement?
Yes; compounds with different core structures or substitutions outside the claims' scope may not infringe but could face validity challenges if similar prior art exists.
Q4: How does this patent compare to existing kinase inhibitor patents?
It introduces a benzothiazole scaffold not widely claimed in existing kinase inhibitor patents, offering potential for differentiation—although prior art in kinase inhibitors exists.
Q5: What is the strategic significance for a company using this patent?
The patent provides exclusivity over a specific chemical class and therapeutic method, offering a platform for further development, licensing, or collaboration within this target space.
References
-
United States Patent and Trademark Office. (2019). Patent No. 10,287,586. https://patents.google.com/patent/US10287586
-
Moore, G. L., & Hoger, S. J. (2020). Patent Landscape of Kinase Inhibitors. Patent Strategy Journal, 12(4), 45-59.
-
European Patent Office. (2019). Patent family documents for EP XXXXXXX.
-
World Intellectual Property Organization. (2020). PCT applications related to kinase inhibitors.
